Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic...
Transcript of Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic...
![Page 1: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/1.jpg)
Anti-fibrotic Therapy in
Hepatitis C
Scott Friedman, M.D.Fishberg Professor of Medicine Chief, Division of Liver Diseases Mount Sinai School of Medicine
Hot Topics in Liver DiseaseHouston, Oct 9, 2010
![Page 2: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/2.jpg)
Hepatic Fibrosis is the Liver’s Wound Healing Response to Many Chronic Injuries
FIBROSIS FIBROSIS Inherited Metabolic Disorders
Excess Vitamin A
Cholestatic Disorders
Immune Disorders
Drugs
Hepatitis Hepatitis
VirusesViruses AlcoholAlcoholNASHNASH
![Page 3: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/3.jpg)
Natural History of Chronic Liver Disease
Chronic hepatitiswith fibrosis
10-50 yrs
Cirrhosis Cirrhosis Normal liverNormal liver
HepatocellularHepatocellular
CarcinomaCarcinoma
LiverLiver
TransplantTransplant
Chronic hepatitis - ~300 million worldwideHCC - fastest rising tumor incidence
![Page 4: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/4.jpg)
OverviewOverview
Challenge # 1: We need better markers of fibrosis stage and activity
Challenge # 2: What makes cirrhosis reversible?
Challenge # 3: We need a ‘proof-of-concept’ anti-fibrotic trial!
![Page 5: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/5.jpg)
Challenge #1: We need better markers of
fibrosis stage and activity!
•• Too much sampling variability and Too much sampling variability and
invasiveness assinvasiveness ass’’d with liver biopsyd with liver biopsy
•• We need markers that are We need markers that are sensitivesensitive, , specific specific
and and respond quickly respond quickly to changes in fibrogenic to changes in fibrogenic
activityactivity
![Page 6: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/6.jpg)
Diagnosis of Hepatic Fibrosis -Current Status
•• Lack of robust, standardized endpointsLack of robust, standardized endpoints is currently is currently the the limiting factorlimiting factor in antifibrotic trials in antifibrotic trials -- need is URGENTneed is URGENT
•• We need We need BIOMARKERSBIOMARKERS, not , not SURROGATESSURROGATES..
•• NonNon--invasive tests (e.g., invasive tests (e.g., ELF, FibrotestELF, Fibrotest) are increasingly ) are increasingly specific for early or late stages, but 25specific for early or late stages, but 25--50% indeterminate 50% indeterminate rate in intermediate stages. rate in intermediate stages.
–– Offer an Offer an ‘‘integratedintegrated’’ readout of fibrosis. readout of fibrosis.
–– May not be sufficient for individual managementMay not be sufficient for individual management
–– BUTBUT, they predict outcomes better than biopsy!, they predict outcomes better than biopsy!
![Page 7: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/7.jpg)
Probe
Liver
ROI
Vibrator
Ribs
Transducter
Fibrosis Assessment with Fibrosis Assessment with
FibroscanFibroscan®®
• Measurements are performed on the
• right lobe of the liver in intercostal position
• The patient is lying supine with the right arm placed behind his head
• Examination time is about 5 minutes
• Interobserver reproducibility
CVS < 10 %,
L = 4 cm Ø = 1 cm
Courtesy of M. Ziol
![Page 8: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/8.jpg)
Sandrin et al, Ultrasound in Biol Med,2003Sandrin et al, Ultrasound in Biol Med,2003
Transient Elastography for Assessment of Hepatic Fibrosis
• Correlates with “stiffness”
• R= 0.71
• ROC= 0.88 for sign fibrosis > F2
• ROC= 0.99 for cirrhosis (F4)
0
5
10
15
20
25
30
Colonne 2
F4
F3
F2
F1
F0
F0F1
F2
F3
F4
Area of fibrosis (%)Area of fibrosis (%) (27 patients)(27 patients)
![Page 9: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/9.jpg)
Principles of 13C Breath Testing
Substrate targets a Substrate targets a
metabolic/biochemical metabolic/biochemical
process which is process which is
affected by presence of affected by presence of
the suspected diseasethe suspected disease
Measure Measure
basebase--line line 1313C/C/1212CC
Drink Drink 1313C marked C marked
substratesubstrate
Rate and magnitude of Rate and magnitude of
change in change in 1313C/C/1212C in C in
exhaled breath exhaled breath
correlates to presence correlates to presence
and severity of the and severity of the
diseasedisease
Human ExhalationHuman Exhalation
1313COCO221212COCO22
1%1% 99%99%
Constant ratio:Constant ratio:1313COCO22
1212COCO2278%78%--NN22
16%16%--OO22
5%5%--COCO22Co
nce
pt
Co
nce
pt
Meth
od
Meth
od
![Page 10: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/10.jpg)
Readout of Methacetin Breath Readout of Methacetin Breath
Test:Test:
![Page 11: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/11.jpg)
Challenge # 2:
What makes Cirrhosis Reversible?
• Not all cirrhosis is the same
• Classification of cirrhosis was never sufficiently refined because it was considered irreversible
• Effective anti-viral therapies have established that even cirrhosis is reversible
![Page 12: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/12.jpg)
Cirrhosis is Reversible!
Evidence in:
• HBV
• HCV
• Secondary biliary cirrhosis
• AIH
• PBC
• Wilson’s disease
• Thalassemia after bone marrow xplant
• Animal models
![Page 13: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/13.jpg)
Improvement in Necroinflammation andFibrosis from Long-term Entecavir Therapy
Chang, Hepatology , 2010
![Page 14: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/14.jpg)
Reversibility of Cirrhosis Following Treatment of Hepatitis C
Poynard et al, Gastroenterology 2002; 122:1303-1313
No
. P
ati
en
tsN
o. P
ati
en
ts
![Page 15: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/15.jpg)
Mallet, V. et. al. Ann Intern MedMallet, V. et. al. Ann Intern Med2008;149:3992008;149:399--403403
Hepatitis C SVR Improves Clinical Outcomes in Cirrhotics, Especially if Cirrhosis Reverses
Responders vsResponders vs
NonNon--RespondersRespondersReversers vsReversers vs
NonNon--ReversersReversers
![Page 16: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/16.jpg)
Improving Liver Fibrosis has a Functional Impact
Roberts et al, Clin Gastro Hep, 2007Roberts et al, Clin Gastro Hep, 2007
SVR of Hepatitis C Lowers HVPG
![Page 17: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/17.jpg)
Hepatic Stellate cell Activation Hepatic Stellate cell Activation --
A Central Event in Liver FibrosisA Central Event in Liver Fibrosis
Normal LiverNormal LiverActivated HSC Activated HSC
with Fibrosis with Fibrosis
Friedman SL and Arthur, Friedman SL and Arthur, Science and MedicineScience and Medicine, 2002, 2002
![Page 18: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/18.jpg)
Pathways of Stellate cell ActivationPathways of Stellate cell Activation
![Page 19: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/19.jpg)
Natural History of Natural History of
Chronic Liver DiseaseChronic Liver Disease
Chronic hepatitisChronic hepatitis
with fibrosiswith fibrosis
1010--50 yrs50 yrs
Cirrhosis Cirrhosis Normal liverNormal liver
HepatocellularHepatocellular
CarcinomaCarcinoma
LiverLiver
TransplantTransplant
AntifibroticAntifibrotic
TherapyTherapy
![Page 20: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/20.jpg)
Challenge # 3 -We need anti-fibrotic treatment in a
‘proof-of-concept’ trial!!
•• Pharma has a short attention span when Pharma has a short attention span when drugs fail (e.g., sepsis therapies, stroke drugs fail (e.g., sepsis therapies, stroke prevention)prevention)
•• Better antiviral therapies for HCV & HBV Better antiviral therapies for HCV & HBV diminish enthusiasm for antidiminish enthusiasm for anti--fibroticsfibrotics
•• ButBut, many pts still need anti, many pts still need anti--fibroticsfibrotics
•• A A ‘‘proof of conceptproof of concept’’ trial will have an trial will have an energizing effect on the fieldenergizing effect on the field
![Page 21: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/21.jpg)
Emerging Therapies for Hepatic Fibrosis
1. Reduce primary disease
2. Downregulate early stellate cell activation
3. Inhibit properties of activated stellate cells: e.g., proliferation, contractility, fibrogenesis
4. Stimulate stellate cell apoptosis
5. Degrade “scar” matrix
![Page 22: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/22.jpg)
Resolution
Friedman SL, J Biol Chem, 2000
Reduce Primary Disease: •• AntiviralsAntivirals
•• Metabolic therapy Metabolic therapy
HCV, NASH
![Page 23: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/23.jpg)
Resolution
Reduce Injury
•• HGF mimeticsHGF mimetics
•• Antioxidants Antioxidants
•• FXR ligands FXR ligands
“Hepatoprotectants”
![Page 24: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/24.jpg)
Resolution
Proliferation
•• PDGFPDGF--R antagonists (MoAb, Gleevec)R antagonists (MoAb, Gleevec)
•• RTK antagonists RTK antagonists –– e.g., e.g., SorafenibSorafenib
![Page 25: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/25.jpg)
Resolution
Contractility
•• ETET--1 & ET1 & ET--1 receptor antagonists1 receptor antagonists
(Bosentan, Thelin)(Bosentan, Thelin)
![Page 26: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/26.jpg)
Resolution
Fibrogenesis
• TGFβ1 & TGFβ1 receptor antagonists
• Hepatocyte growth factor agonists
• AT-Receptor antagonists, ACE Inhibitors
• Adioponectin
• Cannabinoid R1 antagonists
![Page 27: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/27.jpg)
ResolutionHSC Chemotaxis
••PDGFPDGF--R antagonistsR antagonists
••Chemokine antagonistsChemokine antagonists
•• ChemokineChemokine--R antagonistsR antagonists
••Integrin antagonists Integrin antagonists
![Page 28: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/28.jpg)
RESOLUTION
APOPTOSIS?
REVERSION?
INJURY
••Apoptotic ligands, e.g, TRAIL Apoptotic ligands, e.g, TRAIL
••TIMP antagonistsTIMP antagonists
•• Cannabinoids Cannabinoids
![Page 29: Anti-fibrotic Therapy in Hepatitis C - aspe.vb.it antifibrotica Epatite C.pdf · Anti-fibrotic Therapy in Hepatitis C Scott Friedman, M.D. Fishberg Professor of Medicine Chief, Division](https://reader031.fdocuments.us/reader031/viewer/2022020416/5c666d4409d3f252168c5882/html5/thumbnails/29.jpg)
Future Advances in Chronic Hepatitis and Hepatic Fibrosis - 2010
• Improved genetic markers of disease risk
• Better non-invasive markers of injury and fibrosis
• Regenerative therapies for acute and chronic liver failure
• Continued refinements in therapies for viral hepatitis - shorter durations, better AE profiles
• Long term antifibrotics, alone or in combination
• Earlier dx and more cures of HCC